Abstract
The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod
IV in children and adolescents aged from 2 to less than 18 years of age with gMG.
Trial details include:
- The maximum trial duration for each individual participant will be approximately 28
weeks
- The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18
weeks for the treatment response-confirmatory part (Part B)
